

Breakout Group: Thrombotic Risk in COVID-19 Patients

Session Lead: **Geoffrey Barnes, MD, MSc, FACC**

Discussion Points:

- ❖ VTE prevention dosing/intensity in hospitalized patients with COVID-19 (ICU and non-ICU)
- ❖ Potential role for anti-platelet therapy to prevent thrombosis in patients with COVID-19
- ❖ Role of post-hospital thromboprophylaxis for COVID-19
- ❖ Role of thromboprophylaxis for non-hospitalized patients with COVID-19
- ❖ Which biomarkers should be checked to assist with risk stratification or treatment decisions in patients with COVID-19?
- ❖ When should CT, Echocardiography, and Vascular Lab imaging be performed/deferred for patients with COVID-19?

Participants:

Jeffrey S. Berger, MD

Director
Center for the Prevention of CV Disease
NYU Langone Health

Jerrold H. Levy, MD

Professor of Anesthesiology, Critical Care, and
Surgery (Cardiothoracic)
Duke University Medical Centre

Behnood Bikdeli, MD, MS

Vascular Medicine Advanced Fellow
Harvard Medical School

Gregory Piazza, MD, MS

Associate Professor of Medicine
Harvard Medical School

Jean M. Connors, MD

Associate Professor of Medicine
Harvard Medical School

Deborah Siegal, MD, MSc, FRCPC

Associate Professor, Department of Medicine
University Of Ottawa and Ottawa Hospital
Research Institute

Ricardo Garcia-Sanchez, MD

Head, Eliquis & Thrombosis
Worldwide Medical Cardiovascular
Bristol Myers Squibb

Leben Tefera, MD


Staff Physician
Cleveland Clinic

Yogendra Kanthi, MD

Lasker Investigator, Chief - Laboratory of
Vascular Thrombosis & Inflammation
National Heart, Lung and Blood Institute,
National Institutes of Health

Barbara S. Wiggins, PharmD, BCPS

Affiliate Professor
South Carolina College of Pharmacy
Medical University of South Carolina



Breakout Group: Post-Acute Sequelae of SARS-CoV-2 (PASC) or Long COVID

Session Lead: Erica Spatz, MD, FACC

Key Clinical Topics:

- ❖ Autonomic dysfunction (e.g., inappropriate HR response; oxygen delivery/uptake)
- ❖ Endothelial dysfunction (e.g., coronary vasospasm; oxygen delivery/uptake)

Discussion Points:

- ❖ Possible/probable recent myocarditis (i.e., LGE on MRI: should we be looking for it; when?)
- ❖ New ischemic heart disease; new cardiomyopathy (stress-induced) – anything unique to PASC?
- ❖ Medication treatment – tachycardia (beta-blockers, ivabradine); endothelial dysfunction (calcium channel blockers, ACEi, aspirin, statin); microthrombi?
- ❖ Rehabilitation – what can we learn from CPET and studies of ME-CFS with post-exertional fatigue?

Participants:

Andrea Ceresa

Patient representative
Survivor Corps

William K. Cornwell III, MD, MSCS

Assistant Professor of Medicine-Cardiology
University of Colorado

Taylor Doherty, MD

Associate Professor
Section Chief, Allergy and Immunology
University of California, San Diego

Benjamin D. Levine, MD, FACC

Director, Institute for Exercise and
Environmental Medicine
Professor of Medicine and Cardiology
Distinguished Professorship in Exercise Science
University of Texas Southwestern Medical Center

Mitchell Miglis, MD

Clinical Assistant Professor of Neurology
Stanford University

Edward J. Miller, MD, PhD, FACC

Associate Professor of Medicine & Radiology
and Biomedical Imaging
Yale School of Medicine

Oyere K. Onuma MD, MSc

Assistant Professor of Medicine
Yale University School of Medicine

Sean P. Pinney, MD

Professor of Medicine
Co-Director Heart & Vascular Center
Director Advanced Heart Failure & Transplantation
University of Chicago Medicine

Pam R. Taub, MD, FACC


Director of Step Family Foundation Cardiovascular
Rehabilitation and Wellness Center
Associate Professor of Medicine
UC San Diego Health System

Amanda K. Verma, MD, FACC

Assistant Professor of Medicine
Washington University in St. Louis

Annabelle S. Volgman, MD, FACC

McMullan Eybel Endowed Chair for Excellence
in Clinical Cardiology
Professor of Medicine
Medical Director
Rush Heart Center for Women



Breakout Group: Myocarditis/Cardiomyopathy and COVID-19

Session Lead: Larry Allen, MD, FACC

Key Clinical Topics:

- ❖ Acute myocarditis
- ❖ Cardiomyopathies

Discussion Points:

- ❖ Spectrum of acute myocarditis during COVID
- ❖ Frequency of hemodynamically significant and fulminant myocarditis
- ❖ Contribution of stress CM / takotsubo and other non-cytopathic COVID effects to acute myocardial dysfunction
- ❖ Reversibility versus long-term myocardial effects
- ❖ Role of biomarkers, MRI/imaging, and biopsy
- ❖ Acute and long-term treatments

Participants:

Enrico Ammirati, MD, PhD

Attending Physician
Niguarda Hospital, Milano, Italy

Anuradha Lala-Trindade, MD, FACC

Assistant Professor of Medicine, Cardiology
Assistant Professor, Population Health Science
and Policy
Icahn School of Medicine at Mount Sinai

Alexander Lyon, MA, BM, BCh, PhD

Consultant Cardiologist
Royal Brompton Hospital
Senior Lecturer
Imperial College London

Thomas M. Maddox, MD, MSc, FACC

Executive Director of the Healthcare Innovation Lab
BJC HealthCare and Washington University
School of Medicine
Professor of Medicine
Washington University School of Medicine

Elmir Omerovic, MD, PhD

Professor of Cardiology
Sahlgrenska University Hospital
Gothenburg University, Sweden

Valentina O. Puntmann, MD, PhD

Associate Professor
Deputy Head, Goethe CVI Fellowship Programme
Consultant Physician, Cardiologist and
Clinical Pharmacologist
University Hospital Frankfurt, Germany

Saurabh Rajpal, MBBS, MD, FACC

The Ohio State University

Mike Salerno, MD

Associate Professor
UVA Health

Jay W. Schneider, MD, PhD


Discovery Engine/Todd and Karen Wanek
Family Program
for Hypoplastic Left Heart Syndrome
Mayo Clinic

Ravi Shah, MD

Assistant Professor of Medicine
Massachusetts General Hospital

Jitka Starekova, MD

Visiting Assistant Professor
University of Wisconsin-Madison



Breakout Group: Resumption of Exercise and Sports After COVID-19

Session Lead: Eugene Chung, MD, FACC

Key Clinical Topics:

- ❖ What have we learned since the October 2020 updated algorithm ([Kim J et al, JAMA Cardiology](#))
- ❖ What is the role of CMR in RTP screening?

Discussion Points:

- ❖ Pediatric recommendations (12-16yo)
- ❖ Recreational and adult athlete specific recommendations (>35yo)
- ❖ Impact of non-myocarditis effects (e.g., arrhythmia, dyspnea, fatigue, dysautonomia)
- ❖ Impact of long hauler signs and symptoms on RTP
- ❖ Other screening modalities (e.g., wearables)

Participants:

Aaron Baggish, MD

Director, Cardiovascular Performance Program
Director, Cardiovascular Performance Program
Fellowship
Massachusetts General Hospital

Peter N. Dean, MD, FACC

Associate Professor, Department of Pediatrics
University of Virginia

Kimberly G. Harmon, MD

Professor, Departments of Family Medicine and
Orthopaedic and Sports Medicine
University of Washington School of Medicine

Kyle Hornsby, MD

Cardiology | Clinical Cardiac Electrophysiology
Indiana University Health

Jonathan H. Kim, MD, MSc, FACC

Assistant Professor of Medicine
Emory University School of Medicine

Ian Law, MD

Director, pediatric cardiology
University of Iowa Stead Family Children's
Hospital

Matthew W. Martinez, MD

Director
Atlantic Health System Sports Cardiology
Morristown Medical Center

Dermot Phelan, MD, PhD, FACC

Medical Director of Cardiovascular Medicine
Director of Sports Cardiology Center
Co-Director of Hypertrophic Cardiomyopathy
Center
Atrium Health Sanger Heart & Vascular Institute

Eric C. Stecker, MD, MPH, FACC

Associate Professor of Medicine
Division of Cardiovascular Medicine
Oregon Health & Science University, School of
Medicine

Meagan Wasfy, MD, MPH, FACC

Assistant Professor
Harvard Medical School
Associate Director, Cardiovascular Performance
Program
Massachusetts General Hospital